第一个和第三代EGFR-TKI用于治疗晚期非小细胞肺癌的比较:现实研究

相关实验视频

Updated: May 27, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Maitri Shah¹, Kashvi Shah¹, Hetvi Dave¹

¹Pharm.D section, L. M. College of Pharmacy, Ahmedabad, India.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

|February 18, 2025

概括

在印度,奥西米尔提尼布在EGFR突变的转移性非小细胞肺癌 (NSCLC) 方面没有表现出高于格菲提尼布/埃洛提尼布的优势. 虽然它更安全,但其较高的成本并不能由临床有效性来证明是合理的.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床研究临床研究

背景情况:

肺癌是全球主要的死亡原因之一.
表皮生长因子受体 (EGFR) 突变的转移性非小细胞肺癌 (NSCLC) 在印度很普遍.
第一个和第二代EGFR-tyrosine kinase抑制剂 (TKIs),如gefitinib/erlotinib和第三代TKIs,如osimertinib用于治疗.

研究的目的:

为了比较奥西默蒂尼布与格菲蒂尼布/埃洛蒂尼布的临床有效性和安全性,印度患者患有EGFR突变转移性转移性NSCLC.
评估客观反应率 (ORR),疾病控制率 (DCR),无进展生存率 (PFS) 和不良事件 (AE).

主要方法:

西印度的回顾性观察队列研究.
包括EGFR突变转移性转移性NSCLC的患者.
使用ORR,DCR,PFS和AE发生率评估治疗反应.

主要成果:

在ORR (11.11%与25.64%) 或DCR (69.44%与82.05%) 之间没有统计学上显著的差异, osimertinib和gefitinib/erlotinib.
奥西默蒂尼布的PFS中位数为8.43个月,而格菲蒂尼布/埃洛蒂尼布的PFS中位数为10.68个月.
奥西默提尼布显示不良事件发生率较低 (1.94对2.49).

结论:

在这个患者队列中,osmertinib在临床上并不优于gefitinib/erlotinib.
奥西默提尼布显示出更好的安全性概况.
与gefitinib/erlotinib相比, osimertinib 的更高的成本并不能由其临床有效性来证明是合理的.

关键词:

在 EGFR 基因突变.疾病控制率疾病控制率非小细胞肺癌非小细胞肺癌客观的响应率客观的响应率没有进展的生存率.氨酸激酶抑制剂 (TKI) 的使用

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...